Upfront TAVR Shows Promise in Moderate Aortic Stenosis Clinical Trial
Recent clinical trial findings suggest that performing transcatheter aortic valve replacement earlier than traditional guidelines recommend may offer protective benefits for individuals diagnosed with moderate aortic stenosis who present with at least one at-risk feature. The randomized study, known as the PROGRESS trial, evaluated whether early intervention could alter outcomes compared with standard clinical surveillance.
Understanding the Trial Design and Findings
Presented at the Transcatheter Cardiovascular Therapeutics annual conference and simultaneously published in the New England Journal of Medicine, the study investigated patients aged 65 and older. Researchers randomized 744 participants to receive either upfront transfemoral TAVR using the balloon-expandable Sapien 3 platform or once-yearly clinical surveillance. At the two-year mark, the primary composite endpoint of death from any cause or a heart failure event occurred in 16.7 percent of the upfront TAVR group, compared with 23.9 percent of those in the surveillance group.
When looking closely at the individual components of the primary endpoint, researchers noted that the difference was primarily driven by a reduction in heart failure events rather than overall mortality alone. Specifically, heart failure hospitalizations were lower in the TAVR arm. Furthermore, health status measurements evaluated through patient questionnaires favored the early intervention group at both one and two years.
Safety Profiles and Patient Selection
Investigators reported that the procedure maintained a favorable safety profile. The safety event rate at 30 days stood at 5.9 percent, which remained well below the trial’s prespecified performance goal. The majority of these events involved hospitalizations linked to device- or procedure-related complications. However, researchers also observed a new permanent pacemaker implantation rate of 13.0 percent in the upfront TAVR arm versus 10.4 percent in the surveillance group.
Specialists commenting on the trial noted several important limitations. The study excluded individuals with unsuitable anatomy for transfemoral access, significant comorbidities, very low ejection fractions, or prior aortic valve interventions. Consequently, experts emphasize that careful patient selection remains paramount, and lifetime management strategies must be considered since many patients may eventually require repeat procedures.
Broader Implications for Clinical Practice
Among patients initially assigned to clinical surveillance, more than half eventually underwent delayed aortic valve replacement within two years, with a vast majority having progressed to severe disease by that time. Study authors suggest these observations highlight that moderate aortic stenosis is not a benign condition and warrants closer monitoring and earlier referral to specialized valve clinics. While the trial provides valuable preliminary insights into optimal timing, longer-term follow-up planned for up to ten years will be necessary to fully understand the long-term trajectory of these patients.
